Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This molecular biology and phase II trial studies how well imetelstat sodium works in
treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.